Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Crucell N.V. (CRXL) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (141)	1/7/2004 1:06:28 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 560

A very nice deal with a suberb partner. Today I'm happy with the E/$ exchange rate. Really interesting CRXL kept Japan; doesn't avs sell its vaccine there? Wonder how those conversations went. High single to low double digit royalties is impressive for a 'mere' cell line/production method for a conventional flu shot, albeit one with clear advantages. Think royalties go up with increasing sales? This deal structure will also inform the GSK arrangement if malaria succeeds in animal this year; except crxl's share might even be higher because of the novel adeno vector. On the other hand they are using gsk's antigen.